PharmiWeb45m
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WA / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its ...
PharmiWeb9h
Refeyn establishes new mass photometry Scientific Advisory Board to maximize potential of transformative technology
Mass photometry’s unique bioanalytical workflow capabilities recognized by the scientific community, with over 500 scientific ...
PharmiWeb11h
Innovista Health Appoints Managed Care Leader Jigar Desai as New CEO
OAK BROOK, IL / ACCESSWIRE / September 16, 2024 / Innovista Health welcomes Jigar Desai as its new President and Chief ...
PharmiWeb3h
Pharma-Bio Serv Announces Results for the Quarter…
DORADO, PUERTO RICO / ACCESSWIRE / September 16, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support ...
PharmiWeb4h
Nutriband Inc. Authorizes $1M Share Buyback Program
ORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of September ...
PharmiWeb9h
Transgene and BioInvent’s Oncolytic Virus BT-001 S…
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT ...
PharmiWeb10h
RYBREVANT® (amivantamab) plus chemotherapy shows…
Johnson & Johnson today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT®▼ (amivantamab) combined with chemotherapy led to a favourable trend toward improved overall ...
PharmiWeb9h
Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau with an official ...
PharmiWeb1d
Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Melbourne, Australia 16 September 2024: Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces that its lead ...
PharmiWeb8h
DistillerSR Adopts NIST AI Risk Management Framework (RMF) to Ensure the Continued Development of Trustworthy AI Solutions
NIST AI RMF Sets Policies and Guidelines That Underpin the Trusted Development of New DistillerSR AI Capabilities for Literature Review Automation DistillerSR DistillerSR Logo OTTAWA, Ontario, ...
PharmiWeb9h
AAVantgarde announces first patient dosed in First…
AAVantgarde Bio (AAVantgarde), an Italy-based global biotechnology company, announced that the first subject has been dosed in the LUCE-1 trial, a Phase 1/2 open label clinical trial to assess safety ...
PharmiWeb10h
Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference
SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on September 19 ...